microbiology-2016_posters-accepted-abstracts

30 / 42

Page 90
conferenceseries.com
Volume 7, Issue 6 (Suppl) J Bacteriol Parasito
ISSN: 2155-9597 JBP, an open access journal Microbiology 2016
November 28-29, 2016
November 28-29, 2016 Valencia, Spain
7th World Congress on
Microbiology
J Bacteriol Parasitol 2016, 7:6 (Suppl)
Hepatitis C virus (HCV) genotype 1b is associated with a higher hepatocellular carcinoma incidence in
patients with underlying HCV cirrhosis
Arnolfo Petruzziello1, Samantha Marigliano1, Giovanna Loquercio1, Nicola Coppola2, Mauro Piccirillo1, Maddalena Leongito 1, Carmela Cacciapuoti1 and
Francesco Izzo1
1Istituto Nazionale Tumori-Fondazione G. Pascale, Italy
2Second University of Naples, Italy
Background: Hepatocellular carcinoma (HCC) is one of the most common causes of morbidity worldwide, accounting for about
7% of all cancers and over 80% of primary liver cancer. A recent estimate indicates that it is the fifth and the seventh most common
cancer in males and females respectively with approximately one million deaths per year, especially in developing countries and
represents one of the major dreaded complication of chronic liver disease, frequently associated with compensated cirrhosis. It has
been reported, in fact, that approximately 3-4% of HCV chronically infected patients with underlying cirrhosis will develop HCC on
average 30 years after infection.
Aim: The purpose of this study was to clarify the role of hepatitis C virus genotype 1b in HCC development.
Methods: 152 consecutive cases of HCC, fulfilling the criteria from the Barcelona 2000 EASL conference and 147 patients with other
tumors as control group were included in the study. Serum of each patient was evaluated for serology of HCV, viral load estimation
and genotyping.
Results: 80.9% of HCC patients had positive anti-HCV significantly greater than the control group (39.4%; p<0.0001) with a risk of
progression to HCC 6 times higher. Significantly higher rate of anti-HCV seropositivity was shown among male patients with HCC
(90.5%) than among females (59.6%; p<0.0001). Males anti-HCV positive were significantly showed to have about 6 and half times
risk of progression to HCC (OR=6.45; 95% C.I=2.6-15.4) than females. Furthermore, anti-HCV rate increased steadily with the age,
ranging from 5.7% in patients with less of 60 years to 94.3% in patients with over 60 years (p<0.001). On the contrary, this pattern was
not recorded among the control group, suggesting that anti-HCV positive older patients have a risk of progression to HCC almost
13 times higher than the control group (OR=12,8, 95% C.I=5.2-31.4) HCV RNA rate was significantly higher (83.7%) among HCC
patients than in the control group (44.2%, p<0.0001) and the most prevalent genotype was 1b (68.0% in HCC vs. 26.3 in the controls
p<0.001) with a risk of progression almost 6 times greater than patients infected by other genotypes.
Conclusion: HCV genotype 1b is associated with a statistically higher risk of developing HCC if compared to other genotypes. A
prospective study with larger number of samples will be needed to confirm our results.